Orthofix Medical Inc. (OFIX)
| Market Cap | 399.59M -37.7% |
| Revenue (ttm) | 833.19M +3.0% |
| Net Income | -61.72M |
| EPS | -1.53 |
| Shares Out | 40.73M |
| PE Ratio | n/a |
| Forward PE | 15.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 247,597 |
| Open | 9.92 |
| Previous Close | 9.99 |
| Day's Range | 9.67 - 9.99 |
| 52-Week Range | 8.50 - 16.99 |
| Beta | 0.62 |
| Analysts | Buy |
| Price Target | 13.00 (+32.52%) |
| Earnings Date | Nov 9, 2026 |
About OFIX
Orthofix Medical Inc., together with its subsidiaries, operates as a medical technology company in the United States, Italy, the United Kingdom, France, Germany, Brazil, and internationally. It operates through two segments, Global Spine and Global Limb Reconstruction. The Global Spine segment manufactures, distributes, and provides support services for bone growth stimulation devices that enhance bone fusion; designs, develops, and markets a portfolio of spine fixation implant products for use throughout the spinal column; and offers bone graf... [Read more]
Financial Performance
In 2025, Orthofix Medical's revenue was $822.31 million, an increase of 2.85% compared to the previous year's $799.49 million. Losses were -$92.19 million, -26.83% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for OFIX stock is "Buy." The 12-month stock price target is $13.0, which is an increase of 32.52% from the latest price.
News
Orthofix to Report Third Quarter 2026 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2026 financial results on M...
Did Orthofix Medical Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Orthofix Medical Transcript: Canaccord Genuity's 46th Annual Growth Conference
EBITDA has more than doubled in two years, with updated guidance reflecting reimbursement restoration, European MDR inventory purchases, and segment strengths offset by U.S. spine distributor declines. Regulatory reversals and product innovation are driving optimism, with a focus on organic growth and strategic capital allocation.
Orthofix price target lowered to $13 from $18 at Canaccord
Canaccord analyst Caitlin Roberts lowered the firm’s price target on Orthofix (OFIX) to $13 from $18 and keeps a Buy rating on the shares. The firm updated its model following…
Orthofix price target lowered to $14 from $17 at Barrington
Barrington lowered the firm’s price target on Orthofix (OFIX) to $14 from $17 and keeps an Outperform rating on the shares, citing a lower estimate for cash generation and higher…
Orthofix price target lowered to $13 from $15 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on Orthofix (OFIX) to $13 from $15 and keeps a Buy rating on the shares following “relatively mixed” Q2 results. The…
Orthofix Medical Earnings Call Transcript: Q2 2026
Second quarter results showed 5% net sales growth year-over-year, with strong gains in limb reconstruction and spine fixation, and Medicare reimbursement restored for bone growth stimulators. Guidance was raised for both revenue and EBITDA, though softness among smaller U.S. spine distributors remains a headwind.
Orthofix Medical Slides: Q2 2026
Orthofix Medical has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
Orthofix Medical Earnings release: Q2 2026
Orthofix Medical released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Orthofix Medical Quarterly report: Q2 2026
Orthofix Medical has published its Q2 2026 quarterly earnings report on August 5, 2026.
Orthofix Reports Second Quarter 2026 Results Reflecting Continued Operational Progress
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the second quarter ended June 30, 2026, r...
MedTech Pioneer Max Reinhardt Joins eXeX to Drive Canopus Platform Growth
The Johnson & Johnson, Pacira BioSciences and Orthofix executive takes charge of commercial execution as adoption of Canopus by eXeX accelerates across hospital systems in the United States and United...
Orthofix to Participate in Upcoming Investor Conferences
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that Orthofix will participate in the following investor conferenc...
Orthofix to Report Second Quarter 2026 Financial Results
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2026 financial results on ...
Orthofix says CMS revised guidance that withdrew bone growth stimulator changes
In a regulatory filing on Friday, Orthofix (OFIX) stated: “On April 16, 2026, the U.S. Food and Drug Administration issued a final order reclassifying non-invasive bone growth stimulators from Class…
Orthofix price target raised to $17 from $15 at Barrington
Barrington raised the firm’s price target on Orthofix (OFIX) to $17 from $15 and keeps an Outperform rating on the shares after the company disclosed via an 8-K filing on…
Orthofix Medical Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Leadership emphasized operational stabilization, innovation, and commercial optimization. Major launches like Virata and 7D are set to drive growth, while cost discipline and distribution consolidation support profitability. CMS reimbursement changes impact guidance, but long-term outlook remains positive.
Orthofix price target lowered to $15 from $17 at Barrington
Barrington lowered the firm’s price target on Orthofix (OFIX) to $15 from $17 and keeps an Outperform rating on the shares after the company lowered its FY26 guidance and stated…
Orthofix price target lowered to $15 from $18 at Stifel
Stifel lowered the firm’s price target on Orthofix (OFIX) to $15 from $18 and keeps a Buy rating on the shares after the company announced that reimbursement for bone growth…
Orthofix price target lowered to $18 from $20 at Canaccord
Canaccord lowered the firm’s price target on Orthofix (OFIX) to $18 from $20 and keeps a Buy rating on the shares. The firm updated its model following the announcement that…
Orthofix price target lowered to $12 from $14 at TD Cowen
TD Cowen lowered the firm’s price target on Orthofix (OFIX) to $12 from $14 and keeps a Hold rating on the shares after CMS adjusted the relevant reimbursement rates for…
Orthofix cuts FY26 revenue view to $838M-$848M from $850M-$860M
Consensus is $854.43M. Orthofix (OFIX) said in a regulatory filing that the U.S. Food and Drug Administration issued a final order reclassifying non-invasive bone growth stimulators from Class III to…
Orthofix cuts FY revenue guidance, shares down 19.6% to $9.77
09:51 EDT Orthofix (OFIX) cuts FY revenue guidance, shares down 19.6% to $9.77
Orthofix says three-year financial targets no longer applicable
09:49 EDT Orthofix (OFIX) says three-year financial targets no longer applicable
Orthofix Medical Slides: Investor presentation
Orthofix Medical has posted slides in relation to its latest quarterly earnings report, which was published on May 21, 2026.